Your browser is no longer supported. Please, upgrade your browser.
Settings
MNTA Momenta Pharmaceuticals, Inc. daily Stock Chart
MNTA [NASD]
Momenta Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.22 Insider Own1.40% Shs Outstand77.85M Perf Week5.13%
Market Cap1.60B Forward P/E- EPS next Y-0.61 Insider Trans-13.89% Shs Float71.64M Perf Month12.33%
Income-88.10M PEG- EPS next Q-0.48 Inst Own99.90% Short Float6.11% Perf Quarter32.26%
Sales138.90M P/S11.49 EPS this Y-293.70% Inst Trans-0.17% Short Ratio5.14 Perf Half Y50.74%
Book/sh5.00 P/B4.10 EPS next Y51.60% ROA-17.40% Target Price16.17 Perf Year54.14%
Cash/sh4.40 P/C4.66 EPS next 5Y- ROE-23.60% 52W Range11.85 - 20.35 Perf YTD46.95%
Dividend- P/FCF- EPS past 5Y-0.70% ROI-24.70% 52W High0.74% Beta1.66
Dividend %- Quick Ratio8.20 Sales past 5Y16.80% Gross Margin- 52W Low73.00% ATR0.84
Employees279 Current Ratio8.20 Sales Q/Q88.90% Oper. Margin-66.60% RSI (14)69.05 Volatility3.72% 4.57%
OptionableYes Debt/Eq0.00 EPS Q/Q-69.40% Profit Margin-63.40% Rel Volume0.78 Prev Close20.20
ShortableYes LT Debt/Eq0.00 EarningsMay 23 BMO Payout- Avg Volume850.99K Price20.50
Recom2.70 SMA2011.37% SMA5016.28% SMA20029.55% Volume669,004 Change1.49%
Feb-22-18Upgrade Stifel Hold → Buy $18 → $21
Oct-05-17Downgrade Stifel Buy → Hold $22 → $15
Sep-28-17Initiated Goldman Neutral $18
May-22-17Downgrade Barclays Overweight → Equal Weight $20 → $17
Feb-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Jan-31-17Reiterated Barclays Overweight $19 → $20
Nov-22-16Initiated Aegis Capital Hold
Oct-11-16Upgrade Barclays Equal Weight → Overweight $13 → $19
Sep-07-16Downgrade Maxim Group Hold → Sell $6
Jun-06-16Initiated Goldman Neutral $14
Jan-08-16Upgrade Maxim Group Sell → Hold
Nov-13-15Initiated JP Morgan Overweight
Aug-06-15Downgrade Goldman Buy → Neutral
Jun-19-15Reiterated Stifel Buy $26 → $29
Jun-19-15Reiterated Brean Capital Buy $25 → $31
Jun-04-15Initiated Stifel Buy $26
Apr-17-15Reiterated Leerink Partners Outperform $16 → $24
Apr-17-15Reiterated Brean Capital Buy $15 → $25
Feb-18-15Reiterated UBS Buy $18 → $15
Jan-23-15Downgrade Maxim Group Buy → Sell $17 → $7
Mar-20-18 08:30AM  Report: Developing Opportunities within Heico, Global Medical REIT, Acceleron Pharma, Momenta Pharmaceuticals, Silgan, and Weingarten Realty Investors Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-06-18 08:11PM  Edited Transcript of MNTA earnings conference call or presentation 21-Feb-18 3:00pm GMT Thomson Reuters StreetEvents
Mar-05-18 08:00AM  Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences GlobeNewswire
Feb-27-18 07:40AM  Free Research Report as Catalents Revenues Surged 25% and Adjusted EPS Soared 66.7% ACCESSWIRE
Feb-26-18 02:49PM  Momenta Pharmaceuticals Inc (MNTA) Files 10-K for the Fiscal Year Ended on December 31, 2017 GuruFocus.com
Feb-22-18 03:04PM  Momenta Pharmaceuticals Wraps Up a Bleak Year Motley Fool
10:33AM  Stifel: Momenta Pharma's Autoimmune Pipeline Potential Makes It A Buy Benzinga
08:20AM  Todays Research Reports on Stocks to Watch: Momenta Pharmaceuticals and Nektar Therapeutics ACCESSWIRE
07:26AM  Momenta's (MNTA) Earnings & Revenues Surpass Estimates in Q4 Zacks
Feb-21-18 08:29AM  Momenta posts 4Q profit Associated Press
08:00AM  Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update GlobeNewswire
07:40AM  Momenta Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-13-18 05:33PM  Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug TheStreet.com
03:36PM  Teva Pharmaceutical Industries Ltd -- Moody's says launch of second generic version of Copaxone 40mg is credit negative for Teva Moody's
09:09AM  Teva shares drop 3% after rival generic product approved and launched MarketWatch
01:15AM  Momenta Pharmaceuticals Announces FDA Approval and Launch of Glatopa® (glatiramer acetate injection) 40 mg/mL GlobeNewswire
Feb-08-18 08:00AM  Momenta Pharmaceuticals to Webcast Presentation at the LEERINK Partners 7th Annual Global Healthcare Conference GlobeNewswire
Feb-07-18 08:00AM  Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast GlobeNewswire
Jan-31-18 07:18AM  Momenta Up on FDA's Amendment of McPherson Compliance Status Zacks
Jan-30-18 04:02PM  Here's Why Momenta Pharmaceuticals, Inc. Jumped 12% Today Motley Fool +5.18%
08:00AM  Momenta Pharmaceuticals Announces Positive Outcome for Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer GlobeNewswire
Jan-17-18 07:55AM  New Research Coverage Highlights HTG Molecular Diagnostics, Momenta Pharmaceuticals, Black Knight Financial Services, Verint, IBERIABANK, and Sterling Construction Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Jan-12-18 10:08PM  Momenta Pharmaceuticals, Inc. Continues Its Rollercoaster Ride Motley Fool +10.14%
Jan-08-18 06:23PM  Momenta Reports Positive Top-Line Data on Antibody M281 Zacks -13.68%
05:55PM  INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving the Board of Momenta Pharmaceuticals, Inc. Business Wire
01:59PM  Here's Why Momenta Pharmaceuticals, Inc. Reversed Course Today Motley Fool
Jan-05-18 05:06PM  What Happened in the Stock Market Today Motley Fool +18.98%
02:16PM  Why Momenta Pharmaceuticals Rallied 15.6% Today Motley Fool
01:44PM  The Stock Market Is on Autopilot TheStreet.com
01:20PM  Price, Momentum Driving the Action Now TheStreet.com
08:00AM  Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy Volunteers GlobeNewswire
Jan-04-18 08:35AM  Momenta & Mylan to Initiate Trial on Biosimilar of Eylea Zacks
Jan-03-18 05:40PM  Momenta, Mylan plan trial of biosimilar to Regeneron eye drug Reuters
04:05PM  Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept) PR Newswire
Jan-02-18 08:07AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Dec-28-17 08:00AM  Momenta Pharmaceuticals to Webcast Presentation at the 36th Annual J. P. Morgan Healthcare Conference GlobeNewswire
Dec-26-17 07:06AM  Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US : December 26, 2017 Capital Cube
Dec-18-17 05:29PM  Momenta Pharmaceuticals, Inc. Value Analysis (NASDAQ:MNTA) : December 18, 2017 Capital Cube
Dec-15-17 08:01AM  Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : December 15, 2017 Capital Cube
Nov-28-17 12:47PM  ETFs with exposure to Momenta Pharmaceuticals, Inc. : November 28, 2017 Capital Cube
Nov-27-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Nov-22-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Nov-20-17 08:07AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Nov-17-17 08:08AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Nov-15-17 12:07PM  ETFs with exposure to Momenta Pharmaceuticals, Inc. : November 15, 2017 Capital Cube
Nov-10-17 03:30PM  Momenta Pharmaceuticals, Inc.'s Rough Month Motley Fool
08:07AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Nov-08-17 08:00AM  Momenta Pharmaceuticals to Webcast Presentation at the Stifel 2017 Healthcare Conference GlobeNewswire
Nov-03-17 09:59AM  Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Capital Cube
Nov-02-17 03:56PM  Edited Transcript of MNTA earnings conference call or presentation 1-Nov-17 2:00pm GMT Thomson Reuters StreetEvents
03:12PM  Teva Pharmaceutical Industries Ltd -- Moody's says Teva's US generics business will face increased price pressure in 2018; a credit negative Moody's
02:59PM  Momenta's (MNTA) Biosimilar Study Fails, Q3 Loss Narrows Zacks
08:10AM  Today's Research Reports on Stocks to Watch: Momenta Pharmaceuticals and bluebird bio ACCESSWIRE
Nov-01-17 04:30PM  Why Momenta Pharmaceuticals Fell 12.6% Today Motley Fool -12.59%
09:24AM  Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers TheStreet.com
08:29AM  Momenta shares plunge 14% on Q3 profit, revenue misses MarketWatch
08:13AM  Momenta reports 3Q loss Associated Press
08:05AM  Momenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
08:00AM  Momenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept) GlobeNewswire
Oct-30-17 12:04PM  ETFs with exposure to Momenta Pharmaceuticals, Inc. : October 30, 2017 Capital Cube
Oct-19-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Oct-18-17 09:52AM  ETFs with exposure to Momenta Pharmaceuticals, Inc. : October 18, 2017 Capital Cube
08:00AM  Momenta Pharmaceuticals Announces Date of Third Quarter 2017 Financial Results Conference Call and Webcast GlobeNewswire
Oct-17-17 08:05AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Oct-16-17 09:45AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Oct-12-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Oct-06-17 10:57AM  ETFs with exposure to Momenta Pharmaceuticals, Inc. : October 6, 2017 Capital Cube -6.16%
Oct-05-17 11:16AM  Teva Down as Mylan's Copaxone 40 mg Generic Arrives Early Zacks -8.61%
09:30AM  Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017 Capital Cube
08:39AM  Mylans surprise generic win sends Teva, Momenta shares plunging MarketWatch
08:20AM  Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : October 5, 2017 Capital Cube
08:00AM  Today's Research Reports on Trending Tickers: Catabasis Pharmaceuticals and Momenta Pharmaceuticals ACCESSWIRE
Oct-04-17 04:44PM  Why Shopify, Momenta Pharmaceuticals, and MBIA Slumped Today Motley Fool -13.71%
04:11PM  How Mylan's MS-Generic Approval Caused Teva, Momenta To Plunge Investor's Business Daily
12:28PM  A Generic Drug Face-Off Sends Mylan Soaring 19% Motley Fool
09:33AM  Mylan (MYL) Gets FDA Approval for Generic Copaxone 40mg Zacks
08:06AM  Momenta Pharmaceuticals Inc (MNTA): What Does It Mean For Your Portfolio? Simply Wall St.
Oct-03-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Oct-02-17 04:05PM  Momenta Pharmaceuticals Promotes Ganesh V. Kaundinya as Chief Operating Officer and Chief Scientific Officer GlobeNewswire
Sep-29-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Sep-27-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit +5.08%
Sep-25-17 08:05AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Sep-22-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Sep-12-17 07:30AM  Palatin Technologies Announces Appointment of Anthony M. Manning, Ph.D. to Board of Directors PR Newswire
Sep-07-17 08:05AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Sep-06-17 08:09AM  Momenta (MNTA) Up 5.8% Since Earnings Report: Can It Continue? Zacks
Sep-01-17 09:58AM  Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US : September 1, 2017 Capital Cube
Aug-30-17 08:00AM  Momenta Pharmaceuticals to Webcast Presentation at the 2017 Wells Fargo Healthcare Conference GlobeNewswire
Aug-23-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Aug-16-17 08:06AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Aug-14-17 08:05AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Aug-12-17 08:05AM  See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc. Markit
Aug-11-17 08:17PM  Momenta Pharmaceuticals, Inc. Value Analysis (NASDAQ:MNTA) : August 12, 2017 Capital Cube
07:21PM  Edited Transcript of MNTA earnings conference call or presentation 2-Aug-17 2:00pm GMT Thomson Reuters StreetEvents
Aug-10-17 08:22AM  Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US : August 10, 2017 Capital Cube
08:07AM  IHS Markit Score downgrades Momenta Pharmaceuticals Inc to 30 out of 100, ranking positively in only one out of three available IHS Markit categories. Markit
Aug-03-17 05:04PM  Momenta (MNTA) Q2 Loss In Line with Estimates, Sales Beat Zacks
03:52PM  Momenta Pharmaceuticals, Inc. Treads Water in the Second Quarter Motley Fool
Aug-02-17 10:43PM  Momenta reports 2Q loss Associated Press
08:13AM  Momenta reports 2Q loss Associated Press
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company's novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy; M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; and M230, a recombinant trivalent human IgG1 Fc multimer to block tissue damage mediated by immune complexes. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stoner ElizabethDirectorApr 12Option Exercise12.3410,000123,40029,378Apr 13 04:14 PM
Stoner ElizabethDirectorApr 12Sale20.007,714154,28021,664Apr 13 04:14 PM
Stoner ElizabethDirectorApr 10Option Exercise8.855,00044,25022,777Apr 12 04:40 PM
WHEELER CRAIG APresident & CEOApr 10Option Exercise10.4333,334347,674230,913Apr 12 04:41 PM
WHEELER CRAIG APresident & CEOApr 10Sale19.0010,000190,000359,645Apr 12 04:41 PM
WHEELER CRAIG APresident & CEOApr 10Sale19.0033,334633,346197,579Apr 12 04:41 PM
Stoner ElizabethDirectorApr 10Sale19.003,39964,58119,378Apr 12 04:40 PM
Stoner ElizabethDirectorMar 21Option Exercise8.855,00044,25021,176Apr 12 04:40 PM
Stoner ElizabethDirectorMar 21Sale19.003,39964,58117,777Apr 12 04:40 PM
Leicher BruceSVP & General CounselFeb 21Sale15.9072811,575170,843Feb 23 12:26 PM
WHEELER CRAIG APresident & CEOFeb 21Sale16.463,93864,800237,900Feb 23 12:27 PM
Kaundinya Ganesh VenkataramanCOO & CSOFeb 21Sale15.9074511,846495,300Feb 23 12:26 PM
Storer Scott MSVP, CFOFeb 14Sale15.163,97260,21644,783Feb 14 06:15 PM
Kaundinya Ganesh VenkataramanCOO & CSOFeb 14Sale15.164,64570,418496,045Feb 14 06:11 PM
WHEELER CRAIG APresident & CEOFeb 14Sale16.1416,875272,363241,838Feb 14 06:12 PM
Leicher BruceSVP & General CounselFeb 14Sale15.164,63970,327171,571Feb 14 06:09 PM
Kaundinya Ganesh VenkataramanCOO & CSOFeb 12Option Exercise7.4110,10374,863501,031Feb 14 06:11 PM
Kaundinya Ganesh VenkataramanCOO & CSOFeb 12Sale16.203415,524500,690Feb 14 06:11 PM
WHEELER CRAIG APresident & CEOFeb 12Sale16.181,77328,687258,713Feb 14 06:12 PM
Leicher BruceSVP & General CounselFeb 12Sale16.203095,006176,210Feb 14 06:09 PM
Leicher BruceSVP & General CounselFeb 08Option Exercise0.005,3810178,380Feb 12 04:35 PM
Kaundinya Ganesh VenkataramanCOO & CSOFeb 08Option Exercise0.005,6370492,845Feb 12 04:34 PM
WHEELER CRAIG APresident & CEOFeb 08Option Exercise0.0023,1250275,526Feb 12 04:36 PM
Kaundinya Ganesh VenkataramanCOO & CSOFeb 08Sale16.001,91730,672490,928Feb 12 04:34 PM
WHEELER CRAIG APresident & CEOFeb 08Sale15.8910,406165,351260,486Feb 12 04:36 PM
Leicher BruceSVP & General CounselFeb 08Sale16.001,86129,776176,519Feb 12 04:35 PM
Stoner ElizabethDirectorJan 30Option Exercise13.4019,200257,28032,440Feb 01 04:43 PM
Stoner ElizabethDirectorJan 30Sale18.0016,264292,75216,176Feb 01 04:43 PM
WHEELER CRAIG APresident & CEOJan 02Option Exercise7.4125,666190,185278,067Jan 03 04:27 PM
WHEELER CRAIG APresident & CEOJan 02Sale14.1010,000141,000324,690Jan 03 04:27 PM
WHEELER CRAIG APresident & CEOJan 02Sale14.1125,666362,147252,401Jan 03 04:27 PM
Stoner ElizabethDirectorDec 13Sale13.105,50072,05013,240Dec 15 12:27 PM
WHEELER CRAIG APresident & CEONov 21Sale13.354,11654,928252,401Nov 22 10:02 AM
Leicher BruceSVP & General CounselNov 21Sale13.1580310,559172,519Nov 22 10:00 AM
Kaundinya Ganesh VenkataramanCOO & CSONov 21Sale13.1582110,796487,208Nov 22 09:59 AM
WHEELER CRAIG APresident & CEONov 10Sale13.251,85224,539258,602Nov 14 02:09 PM
Leicher BruceSVP & General CounselNov 10Sale13.073554,640173,322Nov 14 02:07 PM
Kaundinya Ganesh VenkataramanCOO & CSONov 10Sale13.123925,143488,029Nov 14 02:05 PM
WHEELER CRAIG APresidentSep 28Option Exercise7.4125,667190,192286,121Oct 02 04:24 PM
WHEELER CRAIG APresidentSep 28Sale19.0210,000190,200282,638Oct 02 04:24 PM
WHEELER CRAIG APresidentSep 28Sale19.0325,667488,443260,454Oct 02 04:24 PM
WHEELER CRAIG APresidentSep 01Option Exercise7.4114,167104,977274,621Sep 05 03:57 PM
WHEELER CRAIG APresidentSep 01Sale17.004507,650292,638Sep 05 03:57 PM
WHEELER CRAIG APresidentSep 01Sale17.0014,167240,839260,454Sep 05 03:57 PM
WHEELER CRAIG APresidentAug 31Option Exercise7.412,30017,043262,754Sep 05 03:57 PM
WHEELER CRAIG APresidentAug 31Sale17.003,45058,650293,088Sep 05 03:57 PM
WHEELER CRAIG APresidentAug 31Sale17.002,30039,100260,454Sep 05 03:57 PM
WHEELER CRAIG APresidentAug 21Sale15.074,11662,008267,173Aug 23 04:36 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchAug 21Sale15.2082112,479488,421Aug 23 04:31 PM
Leicher BruceSVP & General CounselAug 21Sale15.2080212,190173,677Aug 23 04:28 PM
WHEELER CRAIG APresidentAug 10Option Exercise7.419,10067,431282,242Aug 14 02:51 PM
Leicher BruceSVP & General CounselAug 10Sale16.603505,810174,479Aug 14 02:59 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchAug 10Sale16.603876,424489,242Aug 14 02:55 PM
WHEELER CRAIG APresidentAug 10Sale17.006,000102,000289,819Aug 14 02:51 PM
WHEELER CRAIG APresidentAug 10Sale16.9110,953185,219271,289Aug 14 02:51 PM
WHEELER CRAIG APresidentAug 02Option Exercise7.41100741279,961Aug 04 03:31 PM
WHEELER CRAIG APresidentAug 02Sale17.001001,700289,100Aug 04 03:31 PM
WHEELER CRAIG APresidentAug 02Sale17.001001,700279,861Aug 04 03:31 PM
Leicher BruceSVP & General CounselMay 22Sale14.8085912,713174,342May 23 02:47 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchMay 19Sale15.9082113,054489,629May 23 02:51 PM
WHEELER CRAIG APresidentMay 19Sale15.834,11665,156279,861May 23 02:49 PM
Kaundinya Ganesh VenkataramanSenior V.P., ResearchMay 10Sale16.003846,144490,453May 12 02:13 PM
Leicher BruceSVP & General CounselMay 10Sale16.003475,552175,205May 12 02:14 PM
WHEELER CRAIG APresidentMay 10Sale15.771,85229,206283,977May 12 02:13 PM